GT Biopharma Inc
GTBP
|
$3.58
-1.92%
-2.44%
370
|
Manufacturing
(0.0% 1d) (-17.0% 1m) (886.5% 1y) (0.0% 2d) (0.0% 3d) (-1.1% 7d) (205.25% volume)
Earnings Calendar: 2024-03-28
Market Cap: $ 4,942,666
https://www.gtbiopharma.com/
Sec Filling | Patents | 2018 employees
(US) GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based our proprietary TriKE™ NK cell engager platform. Our TriKE™ platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). GT Biopharma has an exclusive worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE™ technology.
ceiling cancer t-cell
add to watch list Paper trade email alert is off
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Last 48 Hours Insiders Buying
RKT P 347 | $12.55 -0.63% 1.12% 1.5M
|
Finance
|
22:30
NWFL | News | $24.21 0.42% 1.99% 9.9K
|
Finance
|
22:00
TGEN P 10000 | $0.68 -0.73% 39.71% 20K
|
Utilities
|
20:01
MNSB P 310 | $15.89 -2.87% -3.02% 46K
|
Finance
|
15:30
RMCF | $3.55 0.28% 0.28% 7.1K
|
Consumer Non-Durables
|
20:10